Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 10, 2006

SciGene Moves to Larger Manufacturing and Research Space

  • SciGene signed a long-term lease on a new manufacturing facility that nearly doubles the size of its current headquarters. “Our new facility provides much needed room for increased design, assembly, and quality control of our products,” notes Terry Gill, director of product manufacturing.

    The new facility will increase assembly area to build its lines of microarray lab equipment, including the BriteSpot™ microarray workstation, Little Dipper™ microarray processor, and the Hybex® microarray incubation system. The larger building will also be used to expand R&D activities on new products.

    The total size of SciGene’s new building is approximately 7,000 sq. ft., including more than 3,000 sq. ft. of assembly and warehouse space. The company will remain in Sunnyvale, CA.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »